JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online July 16, 2008, 10.2967/jnumed.108.052233
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.052233v1
49/8/1277    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, S. J.
Right arrow Articles by Lee, K.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S. J.
Right arrow Articles by Lee, K.-H.
Journal of Nuclear Medicine Vol. 49 No. 8 1277-1282
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.052233

Clinical Investigation

Reversal of Vascular 18F-FDG Uptake with Plasma High-Density Lipoprotein Elevation by Atherogenic Risk Reduction

Su Jin Lee1, Young Keun On2, Eun Jeong Lee1, Joon Young Choi1, Byung-Tae Kim1 and Kyung-Han Lee1

1 Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; and 2 Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence: For correspondence or reprints contact: Kyung-Han Lee, Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwondong, Kangnamgu, Seoul, Korea. E-mail: khnm.lee{at}samsung.com

Vascular 18F-FDG uptake marker represents inflammation in atherosclerotic lesions, but whether inflammation can be reversed by risk-modifying interventions has not, to our knowledge, been demonstrated. In this study, we evaluated the change of vascular 18F-FDG uptake in response to lifestyle intervention on serial PET/CT scans and further assessed how the findings relate to atherogenic risk reduction. Methods: A total of 60 healthy adults underwent 18F-FDG PET/CT scans and atherogenic risk-factor assessment at baseline and again after 17.1 ± 8.3 mo of practicing lifestyle modification. The PET/CT images were evaluated for the presence of vascular 18F-FDG lesions, and vessel–to–blood-pool 18F-FDG ratios were measured. Indices from summed ratios of positive lesions were compared and correlated to atherogenic risk factors. Results: At follow-up, significant reductions in diastolic blood pressure (P < 0.05), total cholesterol (P < 0.05), and low-density lipoprotein level (P < 0.05) and an increase in high-density lipoprotein (HDL) level (P < 0.0001) were demonstrated. On the initial PET/CT scan, 50 of 60 subjects showed 1 or more 18F-FDG–positive lesions (5.9 ± 5.0/subject), leading to a total of 352 vascular sites. On follow-up, 18F-FDG–positive lesions were significantly reduced to 2.1 ± 2.2 sites per subject (P < 0.0001) and a total of 124 sites (64.8% reduction). Follow-up 18F-FDG–positive rates were significantly reduced for the aorta and iliac arteries. In addition, significant reductions in the whole-body 18F-FDG index from 1.39 ± 1.23 to 0.53 ± 0.59 (P < 0.0001) and carotid 18F-FDG index from 0.08 ± 0.16 to 0.03 ± 0.06 (P = 0.01) were shown. The whole-body 18F-FDG index correlated with total cholesterol (P < 0.05) and HDL level (P < 0.05), and the magnitude of reduction in the 18F-FDG index closely correlated to the amount of increase in plasma HDL level (P = 0.005). Conclusion: Our study demonstrated that vascular 18F-FDG uptake is reversed in response to atherogenic risk reduction by lifestyle intervention and that the magnitude of improvement correlates to increases in plasma HDL levels. Thus, serial 18F-FDG PET/CT may be useful for monitoring improvements in the inflammatory component of atherosclerotic lesions in response to risk modification.

Key Words: atherosclerosis • 18F-FDG PET • atherogenic risk factor • risk modification

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. H.F. Rudd, F. Hyafil, and Z. A. Fayad
Inflammation Imaging in Atherosclerosis
Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1009 - 1016.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L. J. Menezes, C. W. Kotze, B. F. Hutton, R. Endozo, J. C. Dickson, I. Cullum, S. W. Yusuf, P. J. Ell, and A. M. Groves
Vascular Inflammation Imaging with 18F-FDG PET/CT: When to Image?
J. Nucl. Med., June 1, 2009; 50(6): 854 - 857.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. J. Fox and H. W. Strauss
One Step Closer to Imaging Vulnerable Plaque in the Coronary Arteries
J. Nucl. Med., April 1, 2009; 50(4): 497 - 500.
[Full Text] [PDF]


Home page
Circ Cardiovasc ImagingHome page
J. H.F. Rudd, K. S. Myers, S. Bansilal, J. Machac, M. Woodward, V. Fuster, M. E. Farkouh, and Z. A. Fayad
Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers: A Prospective Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Imaging Study
Circ Cardiovasc Imaging, March 1, 2009; 2(2): 107 - 115.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.